Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) — Andrew Blauvelt (2017) | RDL Network
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
Patients who were non-responders to etanercept after 12 weeks, as defined by failure to meet sPGA 0/1 (UNCOVER-2) or PASI 75 (UNCOVER-3), achieved high levels of response 12 weeks after switching to ixekizumab. Studies are registered with ClinicalTrials.gov (NCT01597245 and NCT01646177).
Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp
Craig L. Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher Em Griffiths, Hany Elmaraghy, Heidi M. Crane, Himanshu J. Patel, Russel Burge, Gaia Gallo, David Shrom, Ann N. Leung, Chen‐Yen Lin, Kim Papp
Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Clay Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Em Griffiths
Christopher Em Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, C. Paul, Alan Menter, Gregory S. Cameron, J. Erickson, Lu Zhang, Roberta J. Secrest, Susan Ball, Daniel Braun, Olawale Osuntokun, Michael Heffernan, Brian J. Nickoloff, Kim Papp
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.